Pharmacokinetics and Safety of Lefamulin After Single Intravenous Dose Administration in Subjects with Impaired Hepatic Function

2021 ◽  
Author(s):  
Wolfgang W. Wicha ◽  
Thomas C. Marbury ◽  
James A. Dowell ◽  
Jared L. Crandon ◽  
Cathie Leister ◽  
...  
Keyword(s):  
Hepatic Function ◽  
Intravenous Dose ◽  
Single Intravenous Dose ◽  
Dose Administration ◽  
Impaired Hepatic Function

Penetration of Imipenem into Human Pancreatic Juice following Single Intravenous Dose Administration1

Chemotherapy ◽  
1989 ◽  
Vol 35 (2) ◽  
pp. 83-87 ◽  
Author(s):  
Christina Brattström ◽  
Anna-Stina Malmborg ◽  
Gunnar Tydén
Keyword(s):  
Pancreatic Juice ◽  
Intravenous Dose ◽  
Single Intravenous Dose ◽  
Dose Administration

Cytopathology of Cardiac Tissue from Daunomycin-Treated Mice

1971 ◽  
Vol 29 ◽  
pp. 550-551
Author(s):  
Robert H. Liss ◽  
Frances A. Cotton
Keyword(s):  
Cardiac Tissue ◽  
Cardiac Toxicity ◽  
Drug Distribution ◽  
Personal Communication ◽  
Intravenous Dose ◽  
Single Intravenous Dose ◽  
Physiologic Saline ◽  
Histopathologic Changes ◽  
Distribution Studies ◽  
Lung And Kidney

Daunomycin, an antibiotic used in the clinical management of acute leukemia, produces a delayed, lethal cardiac toxicity. The lethality is dose and schedule dependent; histopathologic changes induced by the drug have been described in heart, lung, and kidney from hamsters in both single and multiple dose studies. Mice given a single intravenous dose of daunomycin (10 mg/kg) die 6-7 days later. Drug distribution studies indicate that the rodents excrete most of a single dose of the drug as daunomycin and metabolite within 48 hours after dosage (M. A. Asbell, personal communication).Myocardium from the ventricles of 6 moribund BDF1 mice which had received a single intravenous dose of daunomycin (10 mg/kg), and from controls dosed with physiologic saline, was fixed in glutaraldehyde and prepared for electron microscopy.

scholarly journals Effect of polyaspartic acid on pharmacokinetics of gentamicin after single intravenous dose in the dog.

1996 ◽  
Vol 40 (5) ◽  
pp. 1237-1241 ◽  
Author(s):  
T Whittem ◽  
K Parton ◽  
K Turner
Keyword(s):  
Aspartic Acid ◽  
Elimination Rate ◽  
Volume Of Distribution ◽  
Intravenous Dose ◽  
Pharmacokinetic Parameters ◽  
Therapeutic Drug ◽  
Peripheral Compartment ◽  
Single Intravenous Dose ◽  
Polyaspartic Acid ◽  
Peripheral Tissues

The effects of poly-L-aspartic acid on the pharmacokinetics of gentamicin were examined by using a randomized crossover trial design with the dog. When analyzed according to a three-compartment open model, poly-L-aspartic acid reduced some first-order rate equation constants (A3, lambda 1, and lambda 3), the deep peripheral compartment exit microconstant (k31), the elimination rate constant (k(el)), and the area under the concentration-time curve from 0 to 480 h (AUC0-480) (0.21-, 0.60-, 0.26-, 0.27-, 0.72-, and 0.76-fold, respectively; P < 0.05) but increased the volume of distribution at steady state (Vss), the volume of distribution calculated by the area method (V(area)), the apparent volume of the peripheral compartment (Vp), and all mean time parameters. These results suggested that poly-L-aspartic acid increased the distribution of gentamicin to or binding within the deep peripheral compartment and that poly-L-aspartic acid may have delayed gentamicin transit through the peripheral tissues. In contrast, poly-L-aspartic acid did not alter pharmacokinetic parameters relevant to the central or shallow peripheral compartments to a clinically significant extent. Although gentamicin's pharmacokinetic parameters of relevance to therapeutic drug monitoring were not directly altered, this study has provided pharmacokinetic evidence that poly-L-aspartic acid alters the peripheral distribution of gentamicin. This pharmacokinetic interaction occurred after a single intravenous dose of each drug. Therefore, this interaction should be investigated further, before polyaspartic acid can be considered for use as a clinical nephroprotectant.

USE OF VECURONIUM IN PATIENTS WITH IMPAIRED HEPATIC FUNCTION

1985 ◽  
Vol 63 (Supplement) ◽  
pp. A336
Author(s):  
C. Y. LIN ◽  
Y. P. CHOU ◽  
B. D. SCHREIDER
Keyword(s):  
Hepatic Function ◽  
Impaired Hepatic Function

The Prominent Role of the Liver in the Elimination of Asymmetric Dimethylarginine (ADMA) and the Consequences of Impaired Hepatic Function

2008 ◽  
Vol 32 (6) ◽  
pp. 613-621 ◽  
Author(s):  
Milan C. Richir ◽  
Roderick H. Bouwman ◽  
Tom Teerlink ◽  
Michiel P.C. Siroen ◽  
Theo P.G.M. de Vries ◽  
...  
Keyword(s):  
Asymmetric Dimethylarginine ◽  
Hepatic Function ◽  
Impaired Hepatic Function
Sign in / Sign up

Export Citation Format

Share Document